BYAH
BYAH
Park Ha Biological Technology Co., Ltd. Ordinary SharesIncome Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $1.29M ▲ | $5.54M ▼ | $-4.53M ▲ | -352.26% ▲ | $-7.61 ▲ | $-4.34M ▲ |
| Q2-2025 | $1.24M | $20.9M | $-19.84M | -1.6K% | $-33.76 | $-19.7M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $3.79M ▲ | $5.95M ▲ | $1.96M ▲ | $3.99M ▼ |
| Q2-2025 | $1.35M ▲ | $5.83M ▲ | $1.58M ▲ | $4.25M ▲ |
| Q4-2024 | $547.5K ▼ | $3.08M ▲ | $1.58M ▲ | $1.51M ▲ |
| Q2-2024 | $931.97K | $2.14M | $1.07M | $1.07M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $-4.53M ▲ | $-159.58K ▼ | $2.69M ▲ | $-97.83K ▼ | $2.44M ▲ | $-246.19K ▼ |
| Q2-2025 | $-9.92M | $245.43K | $-3.26M | $3.83M | $803.79K | $243.22K |
5-Year Trend Analysis
A comprehensive look at Park Ha Biological Technology Co., Ltd. Ordinary Shares's financial evolution and strategic trajectory over the past five years.
The company combines very strong product‑level margins, ample cash relative to its small debt load, and solid short‑term liquidity with a differentiated customer experience and a scalable hybrid store–franchise model. Its focus on sensitive and problematic skin, together with a broad product lineup and in‑store services, provides a clear brand story in a large and growing consumer market.
Major risks center on sustained losses, a cost base that is outsized relative to current revenue, and dependence on external equity financing to maintain liquidity and fund expansion. Competitive pressures in the skincare space, limited visible proprietary technology, and a modest asset base amplify these concerns, while negative retained earnings underscore the history of capital consumption rather than creation.
The outlook is that of a young, consumer‑facing brand still in the investment and scaling phase: financially fragile but with strategic plans to grow its footprint, deepen its product portfolio, and improve cost structure through vertical integration. Future performance will hinge on whether Park Ha can translate its high gross margins and customer‑centric model into sufficient sales growth and cost discipline to move toward sustainable cash generation, amid intense competition and evolving consumer behavior.
About Park Ha Biological Technology Co., Ltd. Ordinary Shares
https://www.parkha.cn/The company is an investment holding company that develops skincare products under the “Park Ha” brand in the People’s Republic of China, through its subsidiaries operating in direct product sales and franchise services.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $1.29M ▲ | $5.54M ▼ | $-4.53M ▲ | -352.26% ▲ | $-7.61 ▲ | $-4.34M ▲ |
| Q2-2025 | $1.24M | $20.9M | $-19.84M | -1.6K% | $-33.76 | $-19.7M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $3.79M ▲ | $5.95M ▲ | $1.96M ▲ | $3.99M ▼ |
| Q2-2025 | $1.35M ▲ | $5.83M ▲ | $1.58M ▲ | $4.25M ▲ |
| Q4-2024 | $547.5K ▼ | $3.08M ▲ | $1.58M ▲ | $1.51M ▲ |
| Q2-2024 | $931.97K | $2.14M | $1.07M | $1.07M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $-4.53M ▲ | $-159.58K ▼ | $2.69M ▲ | $-97.83K ▼ | $2.44M ▲ | $-246.19K ▼ |
| Q2-2025 | $-9.92M | $245.43K | $-3.26M | $3.83M | $803.79K | $243.22K |
5-Year Trend Analysis
A comprehensive look at Park Ha Biological Technology Co., Ltd. Ordinary Shares's financial evolution and strategic trajectory over the past five years.
The company combines very strong product‑level margins, ample cash relative to its small debt load, and solid short‑term liquidity with a differentiated customer experience and a scalable hybrid store–franchise model. Its focus on sensitive and problematic skin, together with a broad product lineup and in‑store services, provides a clear brand story in a large and growing consumer market.
Major risks center on sustained losses, a cost base that is outsized relative to current revenue, and dependence on external equity financing to maintain liquidity and fund expansion. Competitive pressures in the skincare space, limited visible proprietary technology, and a modest asset base amplify these concerns, while negative retained earnings underscore the history of capital consumption rather than creation.
The outlook is that of a young, consumer‑facing brand still in the investment and scaling phase: financially fragile but with strategic plans to grow its footprint, deepen its product portfolio, and improve cost structure through vertical integration. Future performance will hinge on whether Park Ha can translate its high gross margins and customer‑centric model into sufficient sales growth and cost discipline to move toward sustainable cash generation, amid intense competition and evolving consumer behavior.

CEO
Xiaoqiu Zhang
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2026-02-20 | Reverse | 1:50 |
Ratings Snapshot
Rating : C-

